SMNR (Semnur Pharmaceuticals) OCF Margin %: 0.00% (As of Mar. 2026)


SMNR Semnur Pharmaceuticals Inc SMNR
8 GF Score
Price $0.65
View Full Analysis

What is Semnur Pharmaceuticals OCF Margin %?

Semnur Pharmaceuticals SMNR -22.62% 8 OCF Margin % is 0.00% as of Mar. 2026. GuruFocus rates SMNR with a GF Score™ of 8/100. Among 948 Biotechnology companies, Semnur Pharmaceuticals ranks worse than 105485.13% on this metric.

OCF Margin % is calculated as Cash Flow from Operations divided by its Revenue. Semnur Pharmaceuticals's Cash Flow from Operations for the three months ended in Mar. 2026 was $-2.67 Mil. Semnur Pharmaceuticals's Revenue for the three months ended in Mar. 2026 was $0.00 Mil. Therefore, Semnur Pharmaceuticals's OCF Margin % for the quarter that ended in Mar. 2026 was 0.00%.

As of today, Semnur Pharmaceuticals's current OCF Yield % is -5.44%.

The historical rank and industry rank for Semnur Pharmaceuticals's OCF Margin % or its related term are showing as below:


SMNR's OCF Margin % is not ranked *
in the Biotechnology industry.
Industry Median: -64.115
* Ranked among companies with meaningful OCF Margin % only.

Semnur Pharmaceuticals OCF Margin % Related Terms

Semnur Pharmaceuticals OCF Margin % Historical Data

* Premium members only.

The historical data trend for Semnur Pharmaceuticals's OCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Semnur Pharmaceuticals OCF Margin % Chart

Semnur Pharmaceuticals Annual Data
Trend Dec22 Dec23 Dec24 Dec25
OCF Margin %
0.00 0.00 0.00 0.00

Semnur Pharmaceuticals Quarterly Data
Dec22 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
OCF Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
SMNR
8GF Score
Semnur Pharmaceuticals Inc SMNR
OCF Margin % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Semnur Pharmaceuticals OCF Margin % Calculation

OCF Margin % is the ratio of Cash Flow from Operations divided by net sales or Revenue, usually presented in percent.

Semnur Pharmaceuticals's OCF Margin for the fiscal year that ended in Dec. 2025 is calculated as

OCF Margin=Cash Flow from Operations (A: Dec. 2025 )/Revenue (A: Dec. 2025 )
=-5.867/0
= %

Semnur Pharmaceuticals's OCF Margin for the quarter that ended in Mar. 2026 is calculated as

OCF Margin=Cash Flow from Operations (Q: Mar. 2026 )/Revenue (Q: Mar. 2026 )
=-2.67/0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about OCF Margin % →
What does a OCF Margin % of 0.00% mean?
Semnur Pharmaceuticals (SMNR) has a OCF Margin % of 0.00% as of Mar. 2026. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on Semnur Pharmaceuticals and its competitors. According to the industry distribution chart, Semnur Pharmaceuticals ranks #999999 out of 948 companies in the Biotechnology industry.
Is Semnur Pharmaceuticals' OCF Margin % too high?
Semnur Pharmaceuticals' current OCF Margin % is 0.00%. Based on the distribution chart, Semnur Pharmaceuticals ranks #999999 out of 948 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Semnur Pharmaceuticals has a GF Score™ of 8/100, reflecting its overall financial health beyond just this single metric.
How does Semnur Pharmaceuticals' OCF Margin % compare to CNTB and ENLV?
According to the Biotechnology industry distribution chart, Semnur Pharmaceuticals ranks #999999 out of 948 companies for OCF Margin %. This places Semnur Pharmaceuticals in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good OCF Margin % for a Biotechnology company?
A good OCF Margin % depends on the Biotechnology industry context. However, OCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high OCF Margin % mean?
A high OCF Margin % can signal that a stock is expensive relative to its fundamentals. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on Semnur Pharmaceuticals and its competitors. Semnur Pharmaceuticals's current OCF Margin % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Semnur Pharmaceuticals stock overvalued right now?
Semnur Pharmaceuticals (SMNR) has a current OCF Margin % of 0.00%. The current OCF Margin % is 0.00%. Semnur Pharmaceuticals' overall GF Score™ is 8/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is OCF Margin % calculated?
OCF Margin % is calculated from a company's financial statements. For Semnur Pharmaceuticals (SMNR), the current OCF Margin % is 0.00% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Semnur Pharmaceuticals Business Description

Address 960 San Antonio Road, Palo Alto, CA, USA, 94303
Semnur Pharmaceuticals Inc is a late-stage clinical biopharmaceutical company focused on developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain. Its main product candidate, SP-102 (10 mg, dexamethasone sodium phosphate viscous gel), is being developed as a non-opioid novel injectable corticosteroid gel formulation for patients with moderate to severe LRP (also known as sciatica), containing no preservatives, surfactants, solvents, or particulates.
8GF Score

Get the complete analysis for SMNR

OCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.65
Price